This monoclonal antibody, which binds to interleukin 6 (IL-6) receptor and blocks the IL-6 mediated inflammatory response, is approved for treatment of rheumatologic disorders and cytokine-release syndrome associated with Chimeric Antigen Receptor T-cell (CAR-T) administration. This evidence concerns the gene IL6 and rheumatic disorder.